What question did this study set out to answer?

To compare overall survival between nivolumab and docetaxel in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC).

September 27, 2015Open Access

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Key Points

To compare overall survival between nivolumab and docetaxel in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC).
Randomized trial involving patients who progressed during or after platinum-based chemotherapy.
Comparison of overall survival rates between nivolumab and docetaxel.
Nivolumab resulted in longer overall survival compared to docetaxel.

Abstract

Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (Funded by Bristol-Myers Squibb; CheckMate 057 ClinicalTrials.gov number, NCT01673867.).

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper